Topic

Mike Hennessy, Sr., is the founder and chairman of MJH Life Sciences.

Articles

Viewpoint: Mike Hennessy, Sr., founder and chairman of MJH Life Sciences, recognizes efforts of the pharmaceutical industry in combatting the COVID-19 pandemic.

How Pharmaceutical Innovation is Saving the World

Margaret M. Faul is vice-president, Drug Product Technologies, Process Development, Amgen.

Carl L. McMillian is vice-president, Toxicology, Drug Disposition, PK/PD, Eli Lilly and Company.

Pierre Boulas is executive director, Product and Technology Development, Biogen.

Reginaldo A. Saraceno is director, Material and Analytical Sciences, Boehringer Ingelheim Pharmaceuticals.

Mary Devlin Capizzi is partner, Faegre Drinker Biddle & Reath LLP.

Maureen T. Cruz is senior manager, Science, Regulation and Policy, Faegre Drinker Biddle & Reath LLP.

The IQ Consortium marks a decade of impactful innovation of collaboration through a network of pharmaceutical companies driving change for the bio/pharmaceutical industry.  

Viewpoint: Precompetitive Collaboration Drives Pharma Industry Innovation

Time sure flies, except when you are waiting for something to happen.

It’s Time to Listen to Science

FDA/FTC collaborate to end false and misleading statements and discuss the future of biosimilars at March 2020 public workshop on a competitive marketplace for biosimilars.

Commentary: A Competitive Marketplace for Biosimilars

Will moving at “warp speed” to develop a vaccine impact efficacy or safety?

How Fast Is Too Fast?

Siegfried Schmitt, PhD, is principal consultant withÂ PAREXEL, Siegfried.Schmitt@parexel.com.

Having a better understanding about compliance will be of benefit when looking for a job or for furthering one’s career, says Siegfried Schmitt, PhD, vice-president, technical, Parexel Consulting.


Starting a Career in the Bio/Pharmaceutical Industry

Industry opportunities are increasing for biosimilars, but companies should pay close attention to delivery device design to facilitate success.


The Design Driver for Biosimilar Adoption

Characterizing and controlling protein aggregation is vital to ensure safety and efficacy of a biopharmaceutical product. In this interview, important aspects of protein aggregation and the tools available to address this issue are discussed.


Keeping Aggregation Under Control

Emergency actions to protect patients and the drug supply may have long-term implications.

Coronavirus Response: Reaction or New Reality?

Bio/pharma researchers mobilize to diagnose and treat patients in pandemic threat.


Viewpoints